Findesk Wiki

ANGIODYNAMICS INC (ANGO)

AngioDynamics develops and markets minimally invasive medical devices across vascular intervention and oncology, with a portfolio spanning mature vascular access products and high-growth technology platforms.

Portfolio structure and market focus

The company operates two segments reflecting its evolution. The Med Device segment comprises established vascular access products—implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters, and blood management devices—serving hospitals and clinics with recurring, stable revenue. The Med Tech segment represents the growth engine, housing newer platforms like Auryon (for peripheral arterial disease), AngioVac and AlphaVac (for mechanical thrombectomy), and NanoKnife (for interventional oncology applications). This dual-segment structure allows the company to maintain steady cash generation from mature offerings while scaling emerging technologies.

Recent momentum and competitive positioning

Auryon, the peripheral artery disease platform, exemplifies the company’s trajectory, growing from launch to over $60 million in projected annual revenue in roughly five years despite competition from established players. NanoKnife, which received FDA clearance in late 2024 and a CPT I code in early 2025, positions AngioDynamics in the expanding interventional oncology space. The vascular access portfolio remains a foundational business, providing recurring customer relationships and cash flow that support investment in higher-margin growth initiatives. Clinical validation through outcomes databases and regulatory approvals underscore product safety and efficacy as competitive moats.

Market drivers and operational dynamics

Adoption of minimally invasive approaches across peripheral vascular disease, venous thromboembolism, and oncology creates sustained demand tailwinds. Hospital economics favor devices that reduce patient recovery time and length of stay, supporting the company’s positioned strength. Reimbursement clarity—particularly the CPT coding for NanoKnife—removes adoption friction. Competition from larger medtech peers and smaller niche players shapes pricing pressure, though differentiation in technology and clinical outcomes remains defensible.

At a glance

  • Dual-segment model: mature vascular access products plus emerging interventional platforms
  • Key growth drivers: Auryon (PAD), AngioVac/AlphaVac (thrombectomy), and NanoKnife (oncology)
  • Recurring vascular access revenue supports investment in higher-margin technology platforms
  • Regulatory approvals and clinical validation support market adoption
  • Operates in minimally invasive procedure markets with structural tailwinds